EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Inflammatory and Epigenetic Biomarkers in Prostate Disease: Current Evidence, Clinical Limitations, and Future Multimarker Strategies

Imola Donath-Miklos iD, Romana Olivia Popețiu iD, Adrian Silviu Crișan iD, Paula Alexandra Vulciu, Oana Știrbu, Roxana Andra Coman iD, Cecilia Avram, Denisa Goldiș, Darius Radu Roman, Alexandru Chioreanu, Radmila Anca Bugari, Dana Zdremțan und 1 weitere

Diagnostics · 16.06.2026 · 16 (12) · 1865

DOI: 10.3390/diagnostics16121865 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 16.06.2026. Verfasst von Imola Donath-Miklos und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology and Life Science, Faculty of Medicine, "Vasile Goldiș" Western University from Arad, B-dul Revoluției nr. 94-96, 310025 Arad, R…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate disease diagnostics increasingly integrate PSA-derived parameters, molecular assays, risk calculators, and multiparametric MRI, yet important limitations remain in distinguishing benign inflammatory changes from clinically significant prostate cancer and in capturing biological heterogeneity. This narrative review summarizes current evidence on inflammatory and epigenetic biomarkers in prostate disease, focusing on YKL-40, mannose-binding lectin, and global DNA methylation/hydroxymethylation. The reviewed evidence indicates that chronic inflammation, innate immune variability, tumor microenvironment remodeling, and epigenetic dysregulation contribute to prostate disease progression and may provide biological information not fully reflected by conventional diagnostic tools. YKL-40 may reflect inflammatory stromal remodeling and angiogenic activity, mannose-binding lectin may represent innate immune variability, while DNA methylation and hydroxymethylation may indicate systemic molecular adaptation and long-term inflammatory imprinting. However, these biomarkers remain largely investigational and should currently be considered adjunctive biological layers rather than validated standalone diagnostic tools. Future studies should prioritize analytical standardization, prospective prostate-specific validation, and assessment of incremental clinical utility beyond PSA, molecular assays, and mpMRI within clearly defined contexts of use.

Schlagwörter

Stichwörter der Autor:innen

DNA hydroxymethylationDNA methylationPSAYKL-40benign prostatic hyperplasiachronic inflammationepigenetic biomarkersmannose-binding lectinmultiparametric MRIprostate cancer

Autor:innen und Institutionen

  • Department of Biology and Life Science, Faculty of Medicine, "Vasile Goldiș" Western University from Arad, B-dul Revoluției nr. 94-96, 310025 Arad, Romania.
  • Department of Internal Medicine, Faculty of Medicine, "Vasile Goldiș" Western University from Arad, B-dul Revoluției nr. 94-96, 310025 Arad, Romania.
  • Department of Intensive Care and Emergency Medicine, Faculty of Medicine, "Vasile Goldiș" Western University from Arad, B-dul Revoluției nr. 94-96, 310025 Arad, Romania.
  • Department of Biochemistry, Faculty of Medicine, "Vasile Goldiș" Western University from Arad, B-dul Revoluției nr. 94-96, 310025 Arad, Romania.
  • Department of Urology, MedLife Humanitas Hospital, Frunzișului Street 77, 400664 Cluj-Napoca, Romania.
  • Faculty of Nursing and Health Sciences, Fundamental Discipline, Anatomy, "Iuliu Hațieganu" University of Medicine and Pharmacy, Victor Babeș Street 8, 400347 Cluj-Napoca, Romania.

ORCID-Profile: Imola Donath-Miklos, Romana Olivia Popețiu, Adrian Silviu Crișan, Roxana Andra Coman, Simona Maria Borta

Zitieren

APA

Donath-Miklos, I., Popețiu, R. O., Crișan, A. S., Vulciu, P. A., Știrbu, O., Coman, R. A., Avram, C., Goldiș, D., Roman, D. R., Chioreanu, A., Bugari, R. A., Zdremțan, D., & Borta, S. M. (2026). Inflammatory and Epigenetic Biomarkers in Prostate Disease: Current Evidence, Clinical Limitations, and Future Multimarker Strategies. Diagnostics, 16(12), 1865. https://doi.org/10.3390/diagnostics16121865

Vancouver

Donath-Miklos I, Popețiu RO, Crișan AS, Vulciu PA, Știrbu O, Coman RA, et al. Inflammatory and Epigenetic Biomarkers in Prostate Disease: Current Evidence, Clinical Limitations, and Future Multimarker Strategies. Diagnostics. 2026;16(12):1865. doi:10.3390/diagnostics16121865

BibTeX
@article{DonathMiklos2026,
  author = {Donath-Miklos, Imola and Popețiu, Romana Olivia and Crișan, Adrian Silviu and Vulciu, Paula Alexandra and Știrbu, Oana and Coman, Roxana Andra and Avram, Cecilia and Goldiș, Denisa and Roman, Darius Radu and Chioreanu, Alexandru and Bugari, Radmila Anca and Zdremțan, Dana and Borta, Simona Maria},
  title = {Inflammatory and Epigenetic Biomarkers in Prostate Disease: Current Evidence, Clinical Limitations, and Future Multimarker Strategies},
  journal = {Diagnostics},
  year = {2026},
  volume = {16},
  number = {12},
  pages = {1865},
  doi = {10.3390/diagnostics16121865}
}
Kostenlos starten →